






WE CLAIM:

1. A compound selected from Formula Ia, Ib, Ic, Id and Ie:



in which:

n is selected from 0, 1 and 2; m is selected from 0, 1, 2 and 3;

W is selected from $-NR_4-$, $-S-$, $-O-$, $-S(O)-$ and $-S(O)_2-$; wherein R_4 is selected from hydrogen and C_{1-6} alkyl;

R_1 is selected from C_{6-10} aryl- C_{0-4} alkyl, C_{5-10} heteroaryl- C_{0-4} alkyl, C_{3-12} cycloalkyl- C_{0-4} alkyl and C_{3-8} heterocycloalkyl- C_{0-4} alkyl; wherein any arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, C_{6-10} aryl, C_{5-10} heteroaryl, C_{3-12} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-6} alkyl, C_{1-6} alkoxy, halo-substituted- C_{1-6} alkyl, halo-substituted- C_{1-6} alkoxy, $-XNR_5R_5$, $-XNR_5XNR_5R_5$, $-XNR_5XOR_5$, $-XOR_5$, $-XSR_5$, $-XS(O)R_5$, $-XS(O)_2R_5$, $-XC(O)NR_5R_5$, $-XOXR_6$ and $-XC(O)R_6$; wherein X is a bond or C_{1-6} alkylene; R_5 is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl- C_{0-4} alkyl; and R_6 is selected from C_{3-8} heterocycloalkyl- C_{0-4} alkyl and C_{5-10} heteroaryl- C_{0-4} alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6} alkyl and $-C(O)OH$; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of R_1 is further optionally substituted by 1 to 5 radicals independently selected from C_{1-6} alkyl and C_{1-6} alkoxy;

R_2 is selected from C_{6-10} aryl- C_{0-4} alkyl, C_{5-10} heteroaryl- C_{0-4} alkyl, C_{3-12} cycloalkyl- C_{0-4} alkyl and C_{3-8} heterocycloalkyl- C_{0-4} alkyl; wherein any arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl of R_2 is optionally substituted by 1 to 3 radicals

independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkynyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkyl, halo-substituted-C₁₋₆alkoxy, C₃₋₈heteroarylC₀₋₄alkyl, -XNR₅R₅, -XOR₅, -XSR₅, -XS(O)R₅, -XS(O)₂R₅, -XSNR₅R₅, -XS(O)NR₅R₅, -XS(O)₂NR₅R₅, -XC(O)OR₅, -XOC(O)R₅, -XC(O)R₅, -XC(O)NR₅XNR₅R₅, -XC(O)NR₅R₅, -XC(O)NR₅XC(O)OR₅, -XC(O)NR₅XNR₅C(O)R₅, -XC(O)NR₅XNR₅C(O)OR₅, -XC(O)NR₅XOR₅, -XC(O)N(XOR₅)₂, -XNR₅C(O)R₅, -XC(O)NR₅R₆, -XC(O)R₆, -XR₇, -XC(O)R₇, -XR₆ and -XC(O)NR₅XR₇; wherein X is a bond or C₁₋₆alkylene; and R₅ is selected from hydrogen, C₁₋₆alkyl and C₃₋₁₂cycloalkyl-C₀₋₄alkyl; R₆ is selected from C₃₋₈heterocycloalkyl-C₀₋₄alkyl and C₅₋₁₀heteroaryl-C₀₋₄alkyl optionally substituted by 1 to 3 radicals selected from C₁₋₆alkyl and -C(O)OH; and R₇ is selected from halo and cyano;

R₃ is selected from halo, hydroxy, -XSR₅, -XS(O)R₅, -XS(O)₂R₅, -XC(O)R₅ and -XC(O)OR₅; wherein X is a bond or C₁₋₆alkylene; and R₅ is selected from hydrogen, C₁₋₆alkyl and C₃₋₁₂cycloalkyl-C₀₋₄alkyl; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

2. The compound of claim 1 in which:

W is selected from -NR₄- and -O-; wherein R₄ is selected from hydrogen and C₁₋₆alkyl;

R₁ is selected from C₆₋₁₀aryl-C₀₋₄alkyl and C₅₋₁₀heteroaryl-C₀₋₄alkyl; wherein any arylalkyl and heteroarylalkyl of R₁ is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, C₅₋₁₀heteroaryl, C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkyl, -XNR₅R₅, -XOR₅, -XSR₅, -XNR₅XNR₅R₅, -XNR₅XOR₅, -XC(O)NR₅R₅, -XOXR₆ and -XC(O)R₆; wherein X is a bond or C₁₋₆alkylene; R₅ is selected from hydrogen, C₁₋₆alkyl and C₃₋₁₂cycloalkyl-C₀₋₄alkyl; and R₆ is selected from C₃₋₈heterocycloalkyl-C₀₋₄alkyl and C₅₋₁₀heteroaryl-C₀₋₄alkyl optionally substituted by 1 to 3 radicals selected from C₁₋₆alkyl and -C(O)OH; wherein any heteroaryl substituent of R₁ is further optionally substituted by 1 to 5 C₁₋₆alkyl radicals;

R₂ is selected from C₆₋₁₀aryl-C₀₋₄alkyl and C₅₋₁₀heteroaryl-C₀₋₄alkyl; wherein any arylalkyl or heteroarylalkyl of R₂ is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkyl, C₃₋₈heteroarylC₀₋₄alkyl, -XNR₅R₅, -XOR₅, -XSR₅, -XS(O)₂NR₅R₅, -XC(O)OR₅, -XOC(O)R₅, -

$\text{XC(O)NR}_5\text{XNR}_5\text{R}_5$, $-\text{XC(O)NR}_5\text{XC(O)OR}_5$, $-\text{XC(O)NR}_5\text{XNR}_5\text{C(O)R}_5$, $-\text{XC(O)NR}_5\text{XNR}_5\text{C(O)OR}_5$, $-\text{XC(O)NR}_5\text{XOR}_5$, $-\text{XC(O)N(XOR}_5)_2$, $-\text{XNR}_5\text{C(O)R}_5$, $-\text{XC(O)NR}_5\text{R}_6$, $-\text{XC(O)R}_6$, $-\text{XR}_7$, $-\text{XR}_6$ and $-\text{XC(O)NR}_5\text{XR}_7$; wherein X is a bond or C_{1-6} alkylene; and R_5 is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl- C_{0-4} alkyl; R_6 is selected from C_{3-8} heterocycloalkyl- C_{0-4} alkyl and C_{5-10} heteroaryl- C_{0-4} alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6} alkyl and $-\text{C(O)OH}$; and R_7 is cyano; and

R_3 is selected from halo, hydroxy, $-\text{XC(O)R}_5$ and $-\text{XC(O)OR}_5$; wherein X is a bond or C_{1-6} alkylene; and R_5 is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl- C_{0-4} alkyl.


3. The compound of claim 1 in which W is selected from $-\text{NH}-$ and $-\text{O}-$; and R_1 is selected from phenyl, benzyl, 5,6,7,8-tetrahydro-naphthalenyl, benzo[1,3]dioxolyl, 1H-indazol-7-yl, indan-4-yl and 1H-indolyl; wherein any arylalkyl and heteroarylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from methoxy, methyl, amino, halo, hydroxymethyl, hydroxy, quinoxaliny, ethyl, pyridinyl, methoxy-phenyl, piperazinyl-carbonyl, ethyl-(2-hydroxy-ethyl)-amino 2-(4-methyl-piperazin-1-yl)-ethoxy, formamyl, isopropyl, methyl-sulfanyl, tri-fluoro-methyl, ethoxy, 3-isopropylamino-propylamino, dimethyl-amino, morpholino, cyclopropyl-methoxy, butoxy, cycloheptyl-oxy and 1,4,5,7-tetramethyl-pyrrolo[3,4-d]pyridazinyl.

4. The compound of claim 1 in which R_2 is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R_2 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-

propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethyl-formamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formyl-pyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonyl-methyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonyl-amino-propyl-formamidyl, acetoxymethyl and 1-carboxy-ethyl-formamidyl.

5. The compound of claim 1 in which n is 0 or 1; m is 0 or 1; and R₃ is selected from halo, hydroxy, -C(O)OH and -C(O)OCH₃.

6. The compound of claim 1 of Formula Ig:



Ig

in which R₂ is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R₂ is optionally substituted by 1 to 3

radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidiny-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethyl-formamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formyl-pyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonyl-methyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonyl-amino-propyl-formamidyl, acetoxy-methyl and 1-carboxy-ethyl-formamidyl.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

BEST AVAILABLE COPY

8. A method for treating a disease in an animal in which inhibition of kinase activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.

9. The method of claim 7 in which the kinase is selected from FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met.

10. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and/or c-Met contributes to the pathology and/or symptomology of the disease.

REST AVAILABLE COPY